Metabolic bone disease in preterm babies: are we underestimating it?”

El-Atawi, Khaled; Elhalik, Mahmoud; Kulkarni, Tushar; Abdelsamad, Amany; Alex, Lois; er,; Satyan, Aswathi; Zakareya, Ahmed

doi:10.15406/jpnc.2019.09.00372

Cited by 3 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main transfer of calcium and phosphorous, needed for bone health, occurs primarily during the third trimester of pregnancy with a peak at 34 weeks gestational age [2,4]. This process is mediated by numerous factors, such as vitamin D, parathyroid hormone (PTH), and calcitonin [8,9] (Fig.…”

Section: Risk Factorsmentioning

confidence: 99%

“…Many are asymptomatic and discovered incidentally through biochemical screening or radiographs. Table 2 lists some of the common signs and symptoms associated with MBDP [4–9,10 ▪▪ ,11,12].…”

Section: Clinical Features and Short-term Consequencesmentioning

confidence: 99%

“…It is primarily a disease in preterm infants born before the 32nd completed week of gestation secondary to a lack of calcium and phosphorus acquisition during the third trimester of pregnancy. Calcium and phosphorous acquisition, needed for bone health, occurs primarily during the third trimester of pregnancy [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Catch it before it breaks!: managing metabolic bone disease of prematurity

Kehinde

Marinescu²,

Turchi

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review Metabolic bone disease of prematurity, commonly referred to as osteopenia of prematurity, remains prevalent in the neonatal intensive care unit (NICU) despite recent medical advances. It is estimated that up to 60% of extreme low birth weight and 20% of very low-birth-weight infants have metabolic bone disease of prematurity. Often silent, it typically presents with poor growth, increased ventilator dependency and fractures. Clinical sequalae, such as short stature can extend into young adulthood. There is no universal consensus by neonatal intensive care unit clinicians on the screening, diagnosis, or treatment for metabolic bone disease of prematurity. The disease is often diagnosed late by radiographs or incidentally in this highly fragile population. Recent findings Suggest screening using DEXA (dual-energy X-ray absorptiometry) scans or ultrasound, in combination with serum markers like alkaline phosphatase, phosphorous levels, parathyroid hormone, and tubular reabsorption of phosphate, might identify at-risk babies earlier. The use of protocol-based screenings may aid in early diagnosis. Summary We present a review of the risk factors, recent screening methods, diagnosis and management of this prevalent, clinically relevant diagnosis, as well as propose a protocol for the early screening and management of this silent disease.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Section: Clinical Features and Short-term Consequencesmentioning

confidence: 99%

See 1 more Smart Citation

Catch it before it breaks!: managing metabolic bone disease of prematurity

Kehinde

Marinescu²,

Turchi

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

show abstract

“…Renal TRP (Tubular Reabsorption of Phosphate) more than 95% suggest that there might be insufficient supplementation of either calcium or phosphate. 31 Moreover, Calcium to creatinine or Phosphorus to creatinine ratios could be used to screen for MBD, however they should be interpreted cautiously as they are influenced by the nutritional supplementation and medications such as loop diuretics and theophylline. 32 Despite the fact that, DEXA can accurately identify those who are at risk of developing fractures, and it being a reliable modality to assess the bone mineralization status, 33 there are many obstacles that impede its use as a universal screening device for MBD.…”

Section: Screening Monitoring and Diagnosingmentioning

confidence: 99%

Untitled

2019

JPNC

View full text Add to dashboard Cite

show abstract

Enfermedad ósea metabólica del prematuro: revisión de tema

Galvis-Blanco¹,

Bueno²,

Villarreal-Gómez³

et al. 2022

Rev Medicas UIS

View full text Add to dashboard Cite

La enfermedad ósea metabólica del prematuro es una patología multifactorial que representa una importante causa de morbilidad, cuya prevalencia ha aumentado. Su diagnóstico requiere criterios bioquímicos, radiológicos y, en etapas avanzadas, clínicos; por lo cual, muchos autores recomiendan estrategias de tamizaje y prevención. El objetivo del presente artículo es realizar una revisión de los aspectos más relevantes respecto a la enfermedad ósea metabólica del prematuro, con énfasis en la prevención y tratamiento precoz. Se realizó una revisión bibliográfica con términos MeSH, en las bases de datos de Pubmed, ClinicalKey, ScienceDirect, SciELO y LILACS. Aunque no hay consenso en las pautas de tamizaje, diagnóstico y tratamiento, la principal estrategia usada en la actualidad es el soporte nutricional individualizado que cubra las demandas de calcio, fósforo y vitamina D, asociado a métodos de intervención clínica y seguimiento de bebés de alto riesgo. La comprensión de esta patología permitirá mejorar las estrategias de tamización, diagnóstico precoz, y de esta forma evitará complicaciones.

show abstract

Metabolic bone disease in preterm babies: are we underestimating it?”

Abstract: Neonates who have been deprived of Enteral feeding for a long time such as extremely low birth weight infants, are at high risk of

Cited by 3 publications

References 39 publications

Catch it before it breaks!: managing metabolic bone disease of prematurity

Catch it before it breaks!: managing metabolic bone disease of prematurity

Untitled

Enfermedad ósea metabólica del prematuro: revisión de tema

Contact Info

Product

Resources

About